Q2 EPS Estimates for Cytokinetics Reduced by Leerink Partnrs

Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) - Research analysts at Leerink Partnrs lowered their Q2 2025 earnings estimates for shares of Cytokinetics in a research report issued to clients and investors on Wednesday, May 7th. Leerink Partnrs analyst R. Ruiz now expects that the biopharmaceutical company will earn ($1.34) per share for the quarter, down from their previous forecast of ($1.32). The consensus estimate for Cytokinetics' current full-year earnings is ($5.24) per share. Leerink Partnrs also issued estimates for Cytokinetics' Q3 2025 earnings at ($1.41) EPS, Q4 2025 earnings at ($1.58) EPS, FY2025 earnings at ($5.69) EPS, FY2026 earnings at ($5.25) EPS, FY2027 earnings at ($3.90) EPS and FY2028 earnings at ($0.95) EPS.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.36) EPS for the quarter, beating analysts' consensus estimates of ($1.41) by $0.05. The firm had revenue of $1.60 million during the quarter, compared to the consensus estimate of $2.77 million. The company's revenue for the quarter was up 89.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.33) EPS.

Several other research analysts also recently commented on CYTK. JMP Securities reaffirmed a "market outperform" rating and issued a $78.00 price target on shares of Cytokinetics in a research report on Thursday, April 10th. Evercore ISI raised shares of Cytokinetics to a "strong-buy" rating in a research report on Friday, February 7th. Barclays cut their target price on shares of Cytokinetics from $55.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday. Needham & Company LLC restated a "buy" rating and issued a $72.00 price target on shares of Cytokinetics in a research report on Friday, May 2nd. Finally, Citigroup cut their price objective on shares of Cytokinetics from $86.00 to $80.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Three equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $74.44.

Cytokinetics Stock Performance

CYTK traded up $0.44 during trading on Friday, hitting $32.13. The stock had a trading volume of 2,255,005 shares, compared to its average volume of 1,671,227. The firm has a market cap of $3.84 billion, a PE ratio of -5.97 and a beta of 0.81. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics has a 12 month low of $31.67 and a 12 month high of $63.46. The company has a 50 day simple moving average of $39.94 and a 200-day simple moving average of $45.78.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Fifth Third Bancorp boosted its position in Cytokinetics by 42.2% during the first quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 291 shares during the period. State of Michigan Retirement System raised its stake in Cytokinetics by 1.1% in the first quarter. State of Michigan Retirement System now owns 28,200 shares of the biopharmaceutical company's stock valued at $1,133,000 after purchasing an additional 300 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in Cytokinetics by 0.9% in the first quarter. Louisiana State Employees Retirement System now owns 33,100 shares of the biopharmaceutical company's stock valued at $1,330,000 after purchasing an additional 300 shares in the last quarter. State of Alaska Department of Revenue raised its stake in Cytokinetics by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 13,820 shares of the biopharmaceutical company's stock valued at $555,000 after purchasing an additional 365 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its stake in shares of Cytokinetics by 189.8% during the fourth quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 374 shares in the last quarter.

Insider Activity at Cytokinetics

In other news, EVP Andrew Callos sold 3,341 shares of Cytokinetics stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $43.27, for a total transaction of $144,565.07. Following the completion of the sale, the executive vice president now owns 64,434 shares in the company, valued at $2,788,059.18. The trade was a 4.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Fady Ibraham Malik sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $45.98, for a total transaction of $91,960.00. Following the transaction, the executive vice president now owns 116,071 shares of the company's stock, valued at approximately $5,336,944.58. This represents a 1.69% decrease in their position. The disclosure for this sale can be found here. Insiders sold 95,362 shares of company stock valued at $3,899,118 in the last ninety days. Insiders own 2.70% of the company's stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.